Transfection News and Research

RSS

Techulon signs license with Virginia Tech Intellectual Properties to market DNA delivery platform

Techulon Inc., a life sciences company based in the Virginia Tech Corporate Research Center, has signed an exclusive license with Virginia Tech Intellectual Properties Inc. to market a new, traceable DNA delivery platform created to deliver genetic medicine to cells while carrying a beacon so scientists can follow its progress.

22 Oct 2010

Altogen Biosystems releases PEG-Liposome siRNA In Vivo Transfection Kit

Altogen Biosystems announced the release of its second generation of in vivo RNAi transfection reagent in the company's popular in vivo delivery product line: PEG-Liposome siRNA In Vivo Transfection Kit. This reagent is also compatible for in vivo transfection of other negatively charged molecules – RNA, DNA, and small proteins.

22 Oct 2010

Study demonstrates potential of nontoxic envelope proteins as an alternative to pseudotype lentiviral vectors

Therapeutic lentiviral vectors are emerging as vital tools for molecular medicine as evidenced by the growing number of clinical trials using these vector systems. From a basic research standpoint, lentiviral vectors are very intriguing substrates. On the one hand, the HIV-1 genome offers expanded cloning capacity and the capability to transduce nondividing cells such as hematopoietic stem cells (HSCs) and neurons.

4 Oct 2010

Access Pharmaceuticals reports significant progress in Cobalamin-targeted drug-delivery program for siRNA therapies

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.

30 Sep 2010

FDA and EMA accept regulatory submissions of vandetanib for advanced medullary thyroid cancer

AstraZeneca today announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted regulatory submissions for review of the investigational drug vandetanib in the treatment of patients with advanced medullary thyroid cancer (MTC). The FDA also granted priority review status for the new drug application and set a Prescription Drug User Fee Act (PDUFA) action date of 7 January 2011.

23 Sep 2010

Promega to provide FuGENE HD Transfection Reagent throughout life science market

Promega Corporation announces it will provide FuGENE HD Transfection Reagent throughout the life science market. The comprehensive, direct use offering from Promega means any life scientist can utilize FuGENE technology with no licensing requirements. FuGENE HD enables the transfection of DNA into many cell types with high efficiency and little-to-no toxicity.

2 Sep 2010

Mirus Bio launches new TransIT-PRO transfection kit for biotherapeutic protein production

Mirus Bio now offers a new transfection kit ideal for biotherapeutic protein production in large pharma and biotech settings. Mirus Bio's new TransIT-PRO™ Kit will decrease time to produce usable protein by maximizing target protein yields through transient transfection.

19 Aug 2010

Life Technologies, CEVEC Pharmaceuticals sign licensing agreement to supply CAP-T expression kits

CEVEC Pharmaceuticals, the developer of a novel human protein expression system derived from amniocytes, announced today the signing of a co-exclusive worldwide licensing agreement with Life Technologies Corporation, a leading provider of innovative life science solutions based in Carlsbad, California. Under the terms of the agreement, Life Technologies and CEVEC will co-operate to offer optimized expression kits based on CEVEC's proprietary CAP-T cells to the global life science research community.

18 Aug 2010

Clontech Laboratories, TET Systems expand license agreement

Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., and TET Systems (TET), a privately-held German biotech company based in Heidelberg, today announced that they have signed an amendment to their existing license agreement. Under the expanded license agreement, Clontech obtains rights to develop, manufacture and commercialize novel Tet Systems products as the Tet-On® 3G™ Inducible Expression System.

26 Jul 2010

Gene therapy holds promise in treating cancer, cardiovascular and neurodegenerative diseases

EUREKA project E! 3371 Gene Transfer Agents has made great advances in the development of novel non-viral carriers able to introduce genetic material into the target cells.

25 Jun 2010

Vandetanib extends Progression Free Survival in ZETA phase III study for advanced medullary thyroid cancer

Results from ZETA, a phase III study in patients with advanced medullary thyroid cancer (MTC), showed that treatment with the investigational drug vandetanib significantly extended Progression Free Survival (PFS), the primary endpoint of the study, by demonstrating a 54% reduction in the rate of progression compared to placebo.

8 Jun 2010

MaxCyte STX Scalable Transfection System acquired by CCS Cell Culture Service

MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, is pleased to announce that CCS Cell Culture Service GmbH has acquired the MaxCyte® STX™ Scalable Transfection System to develop and optimize cells for the pharmaceutical industry.

12 May 2010

Goodwin Biotechnology, Hyprocell sign collaborative agreement to strengthen clinical development services

Goodwin Biotechnology Inc., a full service contract biomanufacturing company, and Hyprocell LLC, a clinical cell line development services company, jointly announced today their collaborative agreement to create a business model enabling customers to access their one stop shop services.

28 Apr 2010

S1P5 may serve as future strategy in biotherapy for esophageal cancer: Study

Esophageal cancer is one of the most common malignancies worldwide. Its mortality is very high due to relatively late diagnosis and inefficient treatment. The ability to reverse the outcome of esophageal cancer is limited due to a poor understanding of its biology. Progression of esophageal cancer may be associated with sphingosine 1-phosphate and its receptors S1P1-5, which play an important role in other cancers.

20 Apr 2010

MaxCyte, Medinet agree to amend License, Development and Supply Agreement

MaxCyte, Inc., and Medinet Co. Ltd., announced today that they have agreed to amend their License, Development and Supply Agreement for expansion of Medinet's right to use MaxCyte's cell loading technology in Asia Pacific markets.

9 Apr 2010

Indispensable role of Mindin in innate and adaptive immunity

Mindin has an indispensable role in both innate and adaptive immunity. A research group in China investigated regulation of mindin expression and the signaling pathway involved. mRNA expression of mindin was upregulated during dextran sulfate sodium induced mouse intestinal inflammation. Stimulation with CpG-ODN (a known TLR-9 ligand) induced upregulation of mindin expression in RAW 264.7 cells and significantly increased the NF-κB-luciferase activity in vitro.

31 Mar 2010

Techulon, UC sign worldwide exclusive license agreements to market Glycofect-Transfection Reagent

Techulon Inc., a life sciences company, has signed worldwide exclusive license agreements with the University of Cincinnati to manufacture and sell novel transfection reagents used for research and therapeutic delivery of nucleic acids.

25 Mar 2010

Proteacel acquires exclusive rights to PORE technology from Moffitt Cancer Center

Moffitt Cancer Center and Proteacel LLC announced today that they have entered a licensing agreement under which Proteacel has acquired the exclusive rights to the PORE™ technology for delivery of genes into cells.

18 Mar 2010

Lonza acquires access to PCA technology patent portfolio

Odyssey Thera, Inc., announced today the signing of an agreement with Lonza to make Odyssey Thera's proprietary Protein-fragment Complementation Assay (PCA) technology, as part of compound profiling services, available to life science and drug discovery researchers.

10 Mar 2010

Update on Cardium Therapeutics' plans for commercial development of Generx

Cardium Therapeutics reported today that its Cardium Biologics division provided an update on plans for the continuing commercial development of Generx™ (alferminogene tadenovec, Ad5FGF-4), a DNA-based angiogenic therapy product candidate for patients with coronary artery disease.

27 Jan 2010